CN Patent

CN111201235B — 劳拉替尼游离碱水合物的结晶形式

Assigned to Pfizer Inc · Expires 2023-02-10 · 3y expired

What this patent protects

本发明涉及(10R)‑7‑氨基‑12‑氟‑2,10,16‑三甲基‑15‑氧代‑10,15,16,17‑四氢‑2H‑8,4‑(亚甲桥)(metheno)吡唑并[4,3‑h][2,5,11]苯并氧杂二氮杂环十四炔‑3‑甲腈(劳拉替尼)游离碱水合物的结晶形式(形式24)。本发明还涉及包含形式24的药物组合物，以及使用形式24及此类组合物治疗哺乳动物的异常细胞生长(诸如癌症)的方法。

USPTO Abstract

本发明涉及(10R)‑7‑氨基‑12‑氟‑2,10,16‑三甲基‑15‑氧代‑10,15,16,17‑四氢‑2H‑8,4‑(亚甲桥)(metheno)吡唑并[4,3‑h][2,5,11]苯并氧杂二氮杂环十四炔‑3‑甲腈(劳拉替尼)游离碱水合物的结晶形式(形式24)。本发明还涉及包含形式24的药物组合物，以及使用形式24及此类组合物治疗哺乳动物的异常细胞生长(诸如癌症)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111201235B
Jurisdiction
CN
Classification
—
Expires
2023-02-10
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.